Differentiation Syndrome Associated With Enasidenib
This analysis of data from a phase 1/2 study evaluates potential cases of isocitrate dehydrogenase differentiation syndrome among patients treated with enasidenib for relapsed/refractory acute myeloid leukemia.
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου